Nimitha R Mathew,Francis Baumgartner,Lukas Braun,David O'Sullivan,Simone Thomas,Miguel Waterhouse,Tony A Müller,Kathrin Hanke,Sanaz Taromi,Petya Apostolova,Anna L Illert,Wolfgang Melchinger,Sandra Duquesne,Annette Schmitt-Graeff,Lena Osswald,Kai-Li Yan,Arnim Weber,Sonia Tugues,Sabine Spath,Dietmar Pfeifer,Marie Follo,Rainer Claus,Michael Lübbert,Christoph Rummelt,Hartmut Bertz,Ralph Wäsch,Johanna Haag,Andrea Schmidts,Michael Schultheiss,Dominik Bettinger,Robert Thimme,Evelyn Ullrich,Yakup Tanriver,Giang Lam Vuong,Renate Arnold,Philipp Hemmati,Dominik Wolf,Markus Ditschkowski,Cordula Jilg,Konrad Wilhelm,Christian Leiber,Sabine Gerull,Jörg Halter,Claudia Lengerke,Thomas Pabst,Thomas Schroeder,Guido Kobbe,Wolf Rösler,Soroush Doostkam,Stephan Meckel,Kathleen Stabla,Stephan K Metzelder,Sebastian Halbach,Tilman Brummer,Zehan Hu,Joern Dengjel,Björn Hackanson,Christoph Schmid,Udo Holtick,Christof Scheid,Alexandros Spyridonidis,Friedrich Stölzel,Rainer Ordemann,Lutz P Müller,Flore Sicre-de-Fontbrune,Gabriele Ihorst,Jürgen Kuball,Jan E Ehlert,Daniel Feger,Eva-Maria Wagner,Jean-Yves Cahn,Jacqueline Schnell,Florian Kuchenbauer,Donald Bunjes,Ronjon Chakraverty,Simon Richardson,Saar Gill,Nicolaus Kröger,Francis Ayuk,Luca Vago,Fabio Ciceri,Antonia M Müller,Takeshi Kondo,Takanori Teshima,Susan Klaeger,Bernhard Kuster,Dennis (Dong Hwan) Kim,Daniel Weisdorf,Walter van der Velden,Daniela Dörfel,Wolfgang Bethge,Inken Hilgendorf,Andreas Hochhaus,Geoffroy Andrieux,Melanie Börries,Hauke Busch,John Magenau,Pavan Reddy,Myriam Labopin,Joseph H Antin,Andrea S Henden,Geoffrey R Hill,Glen A Kennedy,Merav Bar,Anita Sarma,Donal McLornan,Ghulam Mufti,Betul Oran,Katayoun Rezvani,Omid Shah,Robert S Negrin,Arnon Nagler,Marco Prinz,Andreas Burchert,Andreas Neubauer,Dietrich Beelen,Andreas Mackensen,Nikolas von Bubnoff,Wolfgang Herr,Burkhard Becher,Gerard Socié,Michael A Caligiuri,Eliana Ruggiero,Chiara Bonini,Georg Häcker,Justus Duyster,Jürgen Finke,Erika Pearce,Bruce R Blazar,Robert Zeiser,Dennis Kim

Correction to: Differential effectiveness of tyrosine kinase inhibitors in 2D/3D culture according to cell differentiation, p53 status and mitochondrial respiration in liver cancer cells

Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth

Publisher Correction: PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation

Correction to: Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1

Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Corrigendum: NDRG1 Inhibition Sensitizes Osteosarcoma Cells to Combretastatin A-4 Through Targeting Autophagy

Corrigendum: the Significance of Transarterial Chemo(embolization) Combined with Tyrosine Kinase Inhibitors and Immune Check Point Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review

Corrigendum to ‘Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics’ [Genes & Diseases10 (2023) 1367–1401]

Corrigendum to "A Novel Inhibitor of MDM2 Oncogene Blocks Metastasis of Hepatocellular Carcinoma and Overcomes Chemoresistance" [genes Dis 694 (2019) 419-430].

Correction: Loss of EGFR Signaling-Regulated Mir-203 Promotes Prostate Cancer Bone Metastasis and Tyrosine Kinase Inhibitors Resistance

[Corrigendum] Enhanced antitumor activity by the combination of dasatinib and combretastatin A‐4 in vitro and in vivo

[Corrigendum] Azurocidin 1 inhibits the aberrant proliferation of triple‐negative breast cancer through the regulation of pyroptosis

Corrigendum: Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis

Correction: Cheng et al. Glutathione S-Transferases S1, Z1 and A1 Serve as Prognostic Factors in Glioblastoma and Promote Drug Resistance through Antioxidant Pathways. Cells 2022, 11, 3232

Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

Erratum To: PDK1-mTOR Signaling Pathway Inhibitors Reduce Cell Proliferation in MK2206 Resistant Neuroblastoma Cells

Erratum: [Corrigendum] Chloroquine potentiates the anticancer effect of sunitinib on renal cell carcinoma by inhibiting autophagy and inducing apoptosis.

Corrigendum: Negatively Regulated by Mir-29C-3p, MTFR1 Promotes the Progression and Glycolysis in Lung Adenocarcinoma Via the AMPK/mTOR Signalling Pathway.

[Corrigendum] The cranberry flavonoids PAC DP‑9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells

Correction to: Novel smac mimetic APG-1387 elicits ovarian cancer cell killing through TNF-alpha, Ripoptosome and autophagy mediated cell death pathway (Journal of Experimental and Clinical Cancer Research (2018) 37 (53) DOI: 10.1186/s13046-018-0703-9)

Corrigendum: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib